Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Array Biopharma Inc Lowers FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance; Issues Q3 Guidance Below Analysts' Estimates-Conference Call


Tuesday, 5 Feb 2013 02:00pm EST 

Array Biopharma Inc announced that for fiscal 2013, it expects revenue to come in about $60 million with loss per share of $0.55. For the third quarter of 2013, it expects $14 million in revenue and a $0.14 loss per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $62 million and EPS of $(0.58) for fiscal 2013; and revenue of $15 million and EPS of $(0.15) for the third quarter of 2013. 

Company Quote

4.86
0.06 +1.25%
19 Dec 2014